TEL AVIV--Compugen announced recently that it had met the first milestone in its Leads platform agreement with Parke-Davis ahead of schedule, which activated an undisclosed milestone payment from Parke-Davis, a division of Warner-Lambert.

Leads is a computational biology platform for the modeling and understanding of molecular mechanisms of life. Late last year Parke-Davis became the first of a planned total of three major pharmaceutical company partners for the Leads platform, under a multiyear, multimillion-dollars-per-year agreement.